Journal of Clinical Oncology
Articles in this Issue
National Cancer Institute's Working Group on Biochemically Recurrent Prostate Cancer: Clinical Trial Design Considerations
PURPOSE Biochemical recurrence (BCR) of prostate cancer (PCa) after definitive surgery and/or radiation (including salvage strategies) is a burgeoning area of clinical research ins...
Reply to: Oxaliplatin Dosing and Toxicity: A Cautionary Perspective on Efficacy
Comment on Human Epidermal Growth Factor Receptor 2–Low Metastatic Breast Cancer Treatment Costs and Cost-Effectiveness
Beyond the Trials: Real-World Considerations for Sentinel Lymph Node Biopsy Omission in Early Breast Cancer
Remission Assessment by Circulating Tumor DNA in Large B-Cell Lymphoma
PURPOSE Large B-cell lymphomas (LBCLs) are curable, but patients with residual disease after therapy invariably experience progression. Ultrasensitive methods to detect circulating...
Reply to: Comment on Human Epidermal Growth Factor Receptor 2–Low Metastatic Breast Cancer Treatment Costs and Cost-Effectiveness
Efficacy and Safety of Long-Term Continuous Nirogacestat Treatment in Adults With Desmoid Tumors: Results From the DeFi Trial
In the phase III placebo-controlled DeFi trial (ClinicalTrials.gov identifier: NCT03785964 ) primary analysis, nirogacestat showed significant improvement versu...
Oxaliplatin Dosing and Toxicity: A Cautionary Perspective on Efficacy
Metformin Active Surveillance Trial in Low-Risk Prostate Cancer
PURPOSE Active surveillance (AS) is a standard management strategy for low-risk prostate cancer (PCa), but a significant proportion of patients ultimately experience disease progre...
Assessing Remission in Diffuse Large B-Cell Lymphoma: Will Minimal Residual Disease Add Value to Positron Emission Tomography?
Ruxolitinib Versus Best Available Therapy in Patients With Steroid-Refractory Acute Graft-Versus-Host Disease: Final Analysis From the Randomized Phase III REACH2 Trial
Approximately 30%-50% of patients develop acute graft-versus-host disease (aGVHD) after allogeneic hematopoietic cell transplantation (Allo-HCT), representing a major limitation of this treatment. Alt...
A Fighter Bigger Than Myeloma
In a disease marked by racial and ethnic disparities, @khancology tells the story of a patient whose multiple myeloma diagnosis and treatment serves as a reminder of the civil liberties progress we ha...